Compass Inc. Class A Common Stock vs Iovance Biotherapeutics Inc. Common Stock — how do they compare? Compass Inc. Class A Common Stock trades at $9.52 (market cap $7.31B), while Iovance Biotherapeutics Inc. Common Stock trades at $13.58 (market cap $6.04B). The key difference: Compass Inc. Class A Common Stock is the larger of the two by market cap, and Iovance Biotherapeutics Inc. Common Stock is trading nearer its 52-week high, Compass Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Compass Inc. Class A Common Stock for 0 Days and Iovance Biotherapeutics Inc. Common Stock for 0 Days on average.
| COMP | IOVA | |
|---|---|---|
Market Cap | $7.31B | $6.04B |
Volume | 15,861,865 | 14,805,993 |
Sector | Real Estate | Health |
52-Week High | $13.58 | $14.82 |
52-Week Low | $6.68 | $1.81 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $10.72B | $5.97B |
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Compass is a technology-enabled residential real estate company. Its platform provides agents with tools for customer relationships, marketing, client service, and transactions, alongside brokerage, title, escrow, and mortgage services.
Read more on COMP →Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →